Headline News

The FDA granted rare pediatric disease and fast track designations to gildeuretinol, an investigational oral therapy for the treatment of Stargardt disease, according to a press release from Alkeus Pharmaceuticals.

In this podcast episode, Tom Serena, chief executive officer of the American Gastroenterological Association, discusses the role of private equity in specialty societies, the hunger to be involved in innovation and more.

The ability of an artificial neural network to predict COPD exacerbations from urine samples was “excellent,” according to results published in ERJ Open Research.

November 20 marks World COPD Day 2024, a worldwide effort with three goals: raising awareness, sharing knowledge and discussing ways to lower disease burden, according to the Global Initiative for Chronic Obstructive Lung Disease.

SAN DIEGO — Combination tobevibart and elebsiran led to “profound and rapid virologic suppression” as well as normalization of alanine aminotransferase at week 24 in chronic hepatitis D virus infection, according to preliminary data.

Dana Ataya, MD, has written more than a hundred songs.

WASHINGTON — Disparities in the use of biologic and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis, including among older, Black and Asian patients, have not changed in 10 years, according to data.

Advancing equitable access to palliative care will require interdisciplinary collaboration and effective communication, according to several leaders in the field.

Two FDA committees overwhelmingly voted to strike down monitoring requirements under a Risk Evaluation and Mitigation Strategy, or REMS, program for clozapine, a medication for individuals with treatment-resistant schizophrenia.

BOSTON — Using virtual asthma coaching improved asthma control in poorly controlled patients, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.